Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126749 · ClinicalTrials.gov registry record · Phase 1
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT01126749 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 92 participants.
The verdict
NCT01126749, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is safety and tolerable when administered to patients with locally advanced or metastatic bladder cancer and to gain preliminary data on whether patients may benefit from this combination.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-04-16 |
| Est. Completion | 2016-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126749
The ClinicalTrials.gov registry entry for NCT01126749 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01126749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01126749 about?
NCT01126749 is a clinical study titled "Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer". The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is safety and tolerable when administe...
What is the current status of trial NCT01126749?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2010-04-16. Estimated completion is 2016-07-20.
What interventions are being tested in trial NCT01126749?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), E7389 (DRUG).
Who is sponsoring clinical trial NCT01126749?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.